Etoposide (VP-16)-related secondary leukemias (t-AML) occur in up to 10 percent of drug-treated patients and are most frequently associated with MLL gene translocations at 11q23. Delineating the mechanism(s) of VP-16-mediated leukemogenesis is an important goal in oncology and is the major focus of this project. Our central hypothesis is that redox cycling of VP-16 initiated by myeloperoxidase (MPO) amplifies the genotoxicity and carcinogenicity of this agent in myeloid precursors which contain high MPO activity. We propose that MPO converts VP-16 to free radical species and oxidized metabolites that induce oxidative DNA damage and initiate recombinogenic events specifically in myeloid precursor stem cells leading to the chromosomal translocations responsible for t-AML. We further hypothesize that antioxidants such as vitamin C or vitamin E homologues will protect against oxidative DNA damage and may prevent t-AML by reducing levels of VP-16 free radical species produced by MPO. Peroxidative activation of the VP-16 E-ring phenol to form phenoxyl and semiquinone radicals, and orthoquinones results in increased DNA strand breakage. It is not known whether enhanced DNA cleavage occurs by interaction of VP-16 oxidation products directly with DNA, by redox cycle-generated reactive oxygen species (ROS), and/or by enhanced inhibition/poisoning of DNA topoisomerase II (topo II). We propose to characterize the precise mechanism(s) by which activation of VP-16 to free radical forms enhances its DNA damaging activity specifically in genomic regions of the MLL gene known to contain breakpoints associated with t-AML.
Specific aims are to: 1. Determine the role of MPO and the bioreductive enzyme NAD(P)H:quinone oxidoreductase (NQO1) in VP-16 metabolic activation, generation of ROS, and oxidative DNA damage in cultured human leukemia cells (HL60, K562) and in normal human CD34+ progenitor cells. 2. Develop an antioxidant recycling system to decrease MPO-generated phenoxyl radicals of VP-16 and attenuate VP-l6-induced oxidative DNA damage. 3. Characterize chemical modifications in topo II upon interaction with oxidatively activated VP-16 that may be responsible for increased DNA strand breakage/recombination events.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA090787-01
Application #
6320061
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Umar, Asad
Project Start
2001-07-01
Project End
2005-06-30
Budget Start
2001-07-01
Budget End
2002-06-30
Support Year
1
Fiscal Year
2001
Total Cost
$311,250
Indirect Cost
Name
University of Pittsburgh
Department
Pharmacology
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Hasinoff, Brian B; Wu, Xing; Patel, Daywin et al. (2016) Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase II? Isoform. J Pharmacol Exp Ther 356:397-409
Yadav, Arun A; Chee, Gaik-Lean; Wu, Xing et al. (2015) Structure-based design, synthesis and biological testing of piperazine-linked bis-epipodophyllotoxin etoposide analogs. Bioorg Med Chem 23:3542-51
Hasinoff, Brian B; Wu, Xing; Yadav, Arun A et al. (2015) Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II). Biochem Pharmacol 93:266-76
Ren, Yulin; Yuan, Chunhua; Deng, Youcai et al. (2015) Cytotoxic and natural killer cell stimulatory constituents of Phyllanthus songboiensis. Phytochemistry 111:132-40
Ren, Yulin; Lantvit, Daniel D; Deng, Youcai et al. (2014) Potent cytotoxic arylnaphthalene lignan lactones from Phyllanthus poilanei. J Nat Prod 77:1494-504
Yadav, Arun A; Wu, Xing; Patel, Daywin et al. (2014) Structure-based design, synthesis and biological testing of etoposide analog epipodophyllotoxin-N-mustard hybrid compounds designed to covalently bind to topoisomerase II and DNA. Bioorg Med Chem 22:5935-49
Hasinoff, Brian B; Wu, Xing; Nitiss, John L et al. (2012) The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II. Biochem Pharmacol 84:1617-26
Yalowich, Jack C; Wu, Xing; Zhang, Rui et al. (2012) The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase II?. Biochem Pharmacol 84:52-8
Zhang, Rui; Wu, Xing; Yalowich, Jack C et al. (2011) Design, synthesis, and biological evaluation of a novel series of bisintercalating DNA-binding piperazine-linked bisanthrapyrazole compounds as anticancer agents. Bioorg Med Chem 19:7023-32
Wu, Xing; Yalowich, Jack C; Hasinoff, Brian B (2011) Cadmium is a catalytic inhibitor of DNA topoisomerase II. J Inorg Biochem 105:833-8

Showing the most recent 10 out of 32 publications